PD-1单抗-话题@MedSci

#PD-1单抗#

77篇内容 | 2697人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1364896, encodeId=95c9136489688, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=59, createdTime=2020-06-13, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364895, encodeId=23e913648951a, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=100, createdTime=2020-06-12, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364894, encodeId=29cb1364894db, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, objectType=article, longId=194255, objectId=475f19425533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475f19425533, replyNumber=0, likeNumber=84, createdTime=2020-05-18, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475f19425533, moduleTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475f19425533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364893, encodeId=a9151364893a7, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=66, createdTime=2020-05-18, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364892, encodeId=0df21364892c3, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=62, createdTime=2020-05-17, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364891, encodeId=28a713648914d, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=君实生物的PD-1单抗特瑞普利治疗尿路上皮癌，补充新药申请被NMPA接受, objectType=article, longId=193853, objectId=823c193853ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=823c193853ea, replyNumber=0, likeNumber=59, createdTime=2020-05-11, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=823c193853ea, moduleTitle=君实生物的PD-1单抗特瑞普利治疗尿路上皮癌，补充新药申请被NMPA接受, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=823c193853ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364890, encodeId=1ddc13648907f, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处, objectType=article, longId=193623, objectId=35ce1936233b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35ce1936233b, replyNumber=0, likeNumber=86, createdTime=2020-05-08, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35ce1936233b, moduleTitle=赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35ce1936233b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364889, encodeId=026613648897a, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, objectType=article, longId=193319, objectId=6adc193319bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6adc193319bd, replyNumber=0, likeNumber=64, createdTime=2020-05-03, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6adc193319bd, moduleTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6adc193319bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364888, encodeId=17f413648887a, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, objectType=article, longId=192250, objectId=940019225097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=940019225097, replyNumber=0, likeNumber=77, createdTime=2020-04-16, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=940019225097, moduleTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=940019225097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364887, encodeId=8346136488ed8, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, objectType=article, longId=192235, objectId=15911922351b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15911922351b, replyNumber=0, likeNumber=65, createdTime=2020-04-16, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15911922351b, moduleTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15911922351b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364886, encodeId=948513648861a, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=191720, objectId=0445191e204e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0445191e204e, replyNumber=0, likeNumber=81, createdTime=2020-04-10, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0445191e204e, moduleTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0445191e204e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364885, encodeId=864a1364885d1, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法, objectType=article, longId=191474, objectId=78ce1914e4eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78ce1914e4eb, replyNumber=0, likeNumber=77, createdTime=2020-04-06, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78ce1914e4eb, moduleTitle=默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78ce1914e4eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364884, encodeId=d1be1364884c0, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=69, createdTime=2020-03-16, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364883, encodeId=98a1136488364, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, objectType=article, longId=189902, objectId=b3c0189902f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c0189902f2, replyNumber=0, likeNumber=65, createdTime=2020-03-14, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c0189902f2, moduleTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c0189902f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364882, encodeId=29c91364882a5, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, objectType=article, longId=188791, objectId=aa9f188e91bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa9f188e91bf, replyNumber=0, likeNumber=72, createdTime=2020-02-27, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa9f188e91bf, moduleTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa9f188e91bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364881, encodeId=b29d1364881a1, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, objectType=article, longId=188481, objectId=680d18848160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680d18848160, replyNumber=0, likeNumber=81, createdTime=2020-02-22, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680d18848160, moduleTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=680d18848160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364880, encodeId=96491364880ba, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, objectType=article, longId=188280, objectId=62191882804d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62191882804d, replyNumber=0, likeNumber=60, createdTime=2020-02-19, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62191882804d, moduleTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62191882804d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364879, encodeId=0a2d13648e9b0, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=73, createdTime=2020-02-16, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364878, encodeId=093013648e8af, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, objectType=article, longId=186455, objectId=16dd186455e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16dd186455e4, replyNumber=0, likeNumber=107, createdTime=2020-01-19, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16dd186455e4, moduleTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16dd186455e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1364877, encodeId=f21413648e714, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, objectTitle=英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌, objectType=article, longId=186378, objectId=17ce1863e8ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17ce1863e8ed, replyNumber=0, likeNumber=109, createdTime=2020-01-18, rootId=0, userName=doctor-chen9582, userId=8fc0211, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17ce1863e8ed, moduleTitle=英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17ce1863e8ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1单抗

2020-05-29

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌

2020-06-13

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-06-12

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出

2020-05-18

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-18

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2020-05-17

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

君实生物的PD-1单抗特瑞普利治疗尿路上皮癌，补充新药申请被NMPA接受

2020-05-11

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处

2020-05-08

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率

2020-05-03

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌

2020-04-16

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点

2020-04-16

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-04-10

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法

2020-04-06

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-03-16

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准

2020-03-14

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

BMS的PD-1单抗Opdivo首次获批治疗食道癌

2020-02-27

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败

2020-02-22

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％

2020-02-19

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-02-16

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查

2020-01-19

doctor-chen9582 (审核中...)

前往app查看评论内容

#PD-1单抗#

英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌

2020-01-18

科室
- - 订阅+
  - 更多科室
工具
服务